Home Protocols Sermorelin Peptide Dosing Guide: Protocol, Timing & Side Effects (2026)
Protocol / Research Dosing Guide
An evidence-based sermorelin protocol guide covering dosing structure, injection timing, cycle length, side effects, and GH/IGF-1 research context for this GHRH peptide.
By Garret GrantFounder & Lead ResearcherLast reviewed June 2026
Sermorelin is a small peptide that copies the first 29 amino acids of the body's natural growth hormone-releasing hormone (GHRH). It is also called GRF 1-29 or sermorelin acetate. The short copy still fits the pituitary gland's GHRH receptor, so it can trigger a normal growth hormone (GH) pulse.
Most research-context protocols use 200-300 mcg once a night, by subcutaneous injection, about 30-60 minutes before bed on an empty stomach. This is meant to ride along with the body's largest natural GH pulse, which happens during early sleep.
Sermorelin has an unusual history. It was FDA-approved in 1990 as a diagnostic agent and again in 1997 as a treatment for childhood growth hormone deficiency (brand name Geref). Serono Laboratories pulled it from the market in 2008 for manufacturing reasons, not safety reasons. As of June 2026, sermorelin still sits in FDA 503A Category 1, which means licensed compounding pharmacies can legally prepare it. That is different from peptides like BPC-157 or CJC-1295, which sit on Category 2 and cannot be compounded.
Common dose
200-300 mcg subQ nightly. Titration usually starts at 100 mcg.
Half-life
About 11-12 minutes. That is why it is given nightly, not weekly.
Reconstitution
3 mL bacteriostatic (BAC) water in a 10 mg vial gives 3 units per 100 mcg on a U-100 insulin syringe.
Timing
30-60 minutes before sleep, on an empty stomach. Insulin and meals blunt the GH pulse.
Regulatory status
503A Category 1 in June 2026 - still legally compoundable. Branded Geref discontinued 2008.
Educational research reference only
This page is an educational research reference, not medical advice or a treatment plan. Sermorelin has historical FDA approvals but no current branded product. Work with a licensed clinician and a 503A or 503B compounding pharmacy if you are exploring sermorelin in a clinical setting.
Sermorelin dosing in research-context protocols centers on nightly subcutaneous (subQ) injections before bed. The FDA-era label set adult-context dosing at 0.2-0.3 mg per day (200-300 mcg). Modern community protocols use a similar range, with some practitioners titrating up to 400-500 mcg in selected cases.
Higher doses do not always produce a bigger GH pulse. The body's natural "off switch" hormone, somatostatin, kicks in when GH rises too high. That feedback caps how much GH a single sermorelin dose can release. This is one reason sermorelin is considered lower-risk than direct GH injections.
Typical Titration Schedule
Why Bedtime, Empty Stomach Matters
The body's biggest natural GH pulse happens during the first hours of deep sleep. Dosing 30-60 minutes before bed lines sermorelin up with that pulse. Insulin from food can blunt the GH response. Most protocols wait at least 60-90 minutes after the last meal. Sermorelin clears the bloodstream in 11-12 minutes, but the GH pulse it triggers lasts longer.
Scheduling Options
Lab monitoring matters
Standard practice is baseline labs (IGF-1 plus a thyroid panel), repeat at week 6, and again at week 12. Untreated hypothyroidism can blunt the GH response. About 6.5% of FDA-era trial participants developed hypothyroidism, which is why thyroid checks were built into the original prescribing pattern.
Affiliate disclosure: PDP may earn a commission when you use eligible supplier links, at no extra cost to you. The math below assumes a default 10 mg sermorelin vial, 3 mL BAC water per vial, and 200 mcg per night.
Recommended USA Supply
Use discount code PEPPAL at eligible peptide supplier checkouts.
Verified SupplierVerified Supplier
Blood TestAt-Home Blood Test
Injection Supplies
Syringes
Insulin syringes.Buy
Swabs
Sterile alcohol pads.Buy
Peptide Fridge
Lockable fridge.Buy
Peptide Case
Travel case.Buy
TSA Travel Case
Cooled travel case.Buy
Companion Supplies & Routine Support
Disclosure: supply links may earn PDP a commission at no cost to you.
Sermorelin Vials (10 mg default)
One 10 mg vial holds 50 doses of 200 mcg. Once reconstituted, the solution should be used within 28 days, so longer cycles need fresh vials roughly once a month.
Insulin Syringes (U-100)
Use 0.3 mL / 30-unit syringes. With 3 mL BAC water, 200 mcg equals 6 units - easy to read on a U-100 syringe.
Bacteriostatic Water
Use 3 mL per 10 mg vial. Most BAC water bottles are 10 mL or 30 mL.
Round up for priming losses, dropped syringes, and protocol adjustments. If you use a 2 mg, 5 mg, 9 mg, or 15 mg vial instead, use the [PepPal calculator](https://www.peppal.app/calculator?compound=sermorelin) to recheck units.
Reconstitution is just adding sterile bacteriostatic (BAC) water to the dry sermorelin powder so it can be drawn into a syringe. The math is the same for any peptide: divide the total peptide amount by the BAC water volume to get the concentration in mcg/mL, then divide your target dose by that concentration to get the draw volume in mL.
Default 10 mg Vial Setup
With 10 mg of sermorelin and 3 mL of BAC water, the concentration is 3,333 mcg/mL. On a U-100 insulin syringe (where 100 units equals 1 mL), the math comes out to clean whole units:
Other Common Vial Sizes
Step-by-Step Reconstitution
01
Wipe the vial stopper
Remove the plastic cap. Wipe the rubber stopper with an alcohol swab and let it dry. 02
Draw BAC water
Use a sterile syringe to draw the planned amount of bacteriostatic water (3 mL for a 10 mg vial). 03
Inject against the wall
Insert the needle at an angle and aim the water at the inside wall of the vial - not directly onto the powder. 04
Let it run down
Let the water flow gently down the side of the vial. Do not spray or force it. 05
Mix slowly
Remove the syringe. Roll the vial between your palms for 30-60 seconds until the powder fully dissolves. Do not shake. 06
Inspect
The solution should be clear and colorless. Discard if it looks cloudy, discolored, or has particles. 07
Label and refrigerate
Store upright at 2-8°C (36-46°F). Write the reconstitution date and the concentration on the label.
Need exact units for a custom setup?
If you have a non-standard vial size or different BAC water volume, use the free PepPal calculator to get the exact draw volume and syringe units.
This sermorelin dosage chart summarizes the common nightly titration schedule from 100 mcg up to 500 mcg, with dose escalation shown by week range. Sermorelin dosage chart showing the phase-based nightly escalation schedule from 100 mcg to 400-500 mcg used as the dosing reference on this page.
Sermorelin works by talking to the pituitary gland, a small gland at the base of the brain that makes growth hormone (GH). The pituitary normally listens for a signal from the brain called GHRH (growth hormone-releasing hormone). When GHRH shows up, the pituitary releases a burst of GH.
Sermorelin is a short copy of GHRH. The natural hormone is 44 amino acids long. Sermorelin uses only the first 29. Despite being shorter, the 29-amino-acid version still fits the GHRH receptor and still triggers a GH pulse. That is the main mechanism.
The Built-in Safety Brake
The body has a natural "off switch" hormone called somatostatin. When GH levels climb too high, somatostatin steps in and quiets the pituitary back down. Because sermorelin works through the body's own GHRH pathway, this off switch stays active. GH levels rise in natural pulses rather than staying flat and elevated.
This is the key difference from direct GH injections. With direct GH, the dose you inject is the dose you get - the off switch is bypassed. With sermorelin, the brake is still on, so the body protects itself from very high GH levels even at higher sermorelin doses.
Pulsatile Release Matters
Healthy growth hormone in the body is pulsatile - it rises and falls in waves, with the biggest waves during early sleep. Sermorelin's short half-life (11-12 minutes) actually fits this pattern well. It nudges the pituitary into making a pulse, then clears out fast, leaving the body's own rhythm in place.
Receptor: GHRH receptor on pituitary somatotroph cells. Trigger: cAMP signaling inside the cell, which causes GH release. Brake: Somatostatin feedback keeps GH from climbing too high. Why nightly: Sermorelin clears in minutes, but the GH pulse it triggers fits the natural early-night surge.
Sermorelin is typically discussed in two settings: pediatric GH deficiency in the historical FDA-era label, and adult off-label use through 503A or 503B compounding pharmacies for GH optimization, sleep, and body composition. Both should involve a licensed clinician.
Who Generally Avoids Sermorelin
Known allergy to sermorelin or any of the ingredients in the formulation. Pregnancy or breastfeeding. The FDA-era label flagged sermorelin as Pregnancy Category C. There are no controlled studies in pregnant women, and it is unknown whether sermorelin passes into breast milk. Active cancer. GH and IGF-1 can act as growth signals on existing cells. Most protocols screen for active malignancy before starting. Growth hormone deficiency from an intracranial lesion - the FDA-era label specifically said these patients were not studied and were not recommended for sermorelin therapy. Untreated hypothyroidism. This blunts the GH response and should be corrected first. On glucocorticoid therapy. Glucocorticoids can blunt the response to sermorelin per the FDA-era label drug interactions.
Clinical oversight
Sermorelin therapy was, in the FDA-era label, supposed to be carried out under the regular guidance of a physician experienced in growth-hormone-related conditions. That is still the standard expectation for compounded sermorelin in 2026.
Sermorelin has a published safety profile from its FDA-era pediatric clinical trial program. Across 350 patients in those trials, the peptide was generally well-tolerated. Most side effects were mild, local, and resolved on their own.
Common Side Effects
Injection-site reactions (about 1 in 6 participants, roughly 17%): pain, swelling, or redness at the injection site. Usually mild, usually went away on their own. Only 3 of 350 patients stopped treatment because of them.
Less Common Side Effects (each under 1%)
Headache Facial flushing Difficulty swallowing (dysphagia) Dizziness Restlessness or hyperactivity Drowsiness Changes in taste Hives (urticaria) Nausea or vomiting (more often with IV diagnostic use than nightly subQ)
Things to Monitor
Antibody development. About 70% of FDA-era trial participants developed anti-GRF antibodies at least once during treatment. The label noted that these antibodies did not appear to meaningfully reduce sermorelin's effectiveness or cause specific reactions in most participants. Hypothyroidism. About 6.5% of trial participants developed hypothyroidism. Untreated hypothyroidism reduces the body's response to GH stimulation, so baseline and follow-up thyroid labs are standard practice. Allergic reactions. Like any injected peptide, sermorelin can cause local or, rarely, systemic allergic reactions. Stop and seek medical attention for swelling of the face, mouth, or throat, trouble breathing, or widespread hives.
Lower-Risk Profile Compared to Direct GH
Because sermorelin works through the body's own feedback system, the risk of pushing GH or IGF-1 too high is built-in lower than with direct recombinant GH injections. Clinical data also showed no significant abuse or dependence potential.
Most published practitioner reviews and FDA-era clinical context line up on a similar timeline. Sleep and recovery feedback tend to show up first. Body-composition changes take much longer, partly because they depend on weeks of steady GH and IGF-1 elevation, not a single pulse.
Sermorelin has an unusual evidence profile for a research-context peptide. It was actually FDA-approved twice: once in 1990 as a diagnostic agent for GH deficiency, and again in 1997 as a treatment for childhood GH deficiency. The branded version (Geref) was pulled in 2008 for manufacturing reasons, not safety reasons.
So sermorelin has real FDA-era trial data - but most of it is in children. Adult use today rests on practitioner experience, published reviews, and pharmacokinetic (PK) studies, not large modern randomized controlled trials.
FDA-era diagnostic program (1990)
Single-dose IV sermorelin produced rapid, specific GH release in healthy children and a blunted response in GH-deficient children. This is the data that supported sermorelin's diagnostic FDA approval.
FDA-era pediatric treatment program (1997)
Children with growth hormone deficiency received nightly subQ sermorelin at 0.2-0.3 mg/day. Trials showed significant increases in GH release and growth velocity at 6 months, with efficacy reported through 36 months.
Pharmacokinetics (Ishida et al., 2020)
Pooled PK data showed a half-life of about 11-12 minutes after either IV or subQ dosing, plasma clearance of 2.4-2.8 L/min, and rapid time-to-peak after subcutaneous injection.
Adult-context review (Walker, 2006)
Walker's review in Clinical Interventions in Aging discussed sermorelin for adult GH insufficiency, highlighting the pituitary-supportive and feedback-regulated nature of GHRH stimulation versus direct GH replacement.
Modern adult RCT data
Large modern randomized controlled trials in adults are limited after the 2008 commercial discontinuation. Current adult dosing rests on practitioner experience and published reviews rather than fresh Phase 3 trials.
Bottom line: sermorelin has more historical clinical evidence than most peptides discussed in research-use forums, but modern adult evidence is thin. That gap is a real boundary on any specific dosing claim.
Short room-temperature windows (for example during travel) are usually fine, but refrigerate again as soon as possible.
Sermorelin's regulatory status confuses a lot of people. Here is the timeline, as of June 2026:
Compounded vs research-use
Compounded sermorelin from a licensed 503A or 503B pharmacy with a prescription is different from "research use only" (RUO) peptide sold online. Compounded products are intended for human use under clinician supervision. RUO products carry disclaimers that they are not for human use, and the FDA has issued warning letters when sellers cross that line.
Sermorelin, tesamorelin, and CJC-1295 (DAC) all target the same GHRH receptor in the pituitary. They differ in how long they last in the body, how often you inject, and how much modern evidence supports them.
Quick Decision Framework
Sermorelin has the longest historical track record and is currently the most accessible GHRH analogue via compounding pharmacies. Best fit when pulsatile, feedback-controlled GH is the goal. Tesamorelin has the strongest modern RCT evidence, specifically for visceral fat reduction in HIV-associated lipodystrophy. Also legally accessible as an FDA-approved drug. CJC-1295 (DAC) offers the longest dosing interval but sits in 503A Category 2, so it cannot be legally compounded in the U.S. today.
Sermorelin is often discussed alongside ghrelin-receptor peptides like Ipamorelin and GHRP-6, especially when researchers are comparing one-signal vs two-signal GH pulse protocols. For combination context, read the PepPal Peptide Stacking 101 guide before combining compounds.
Ipamorelin Protocol
GH secretagogue that pairs with sermorelin in many community protocols.Read protocol
GHRP-6 Protocol
Older GH secretagogue with stronger appetite effects and a three-times-daily SubQ planning model.Read protocol
Tesamorelin Protocol
Longer-acting GHRH analogue with stronger modern RCT evidence in visceral-fat outcomes.Read protocol
Tesamorelin + Ipamorelin Blend
GHRH analog plus ghrelin-mimetic stack with ratio-specific blend math.Read stack
CJC-1295 (No DAC) Protocol
Short-acting modified GHRH analogue with different pharmacokinetics from sermorelin.Read protocol
GH Pulse Stack
CJC-1295 + Ipamorelin GH pulse stack context page.Read stack
Sermorelin is a GHRH analog that stimulates the GH-axis. Monitoring focuses on IGF-1, glucose handling, thyroid context, lipids, and fluid-retention symptoms.
At-home blood test option
Easy at home option to monitor core metrics during research cycles.
Blood TestAt-Home Blood Test
SiPhox Health
SiPhox Health At-Home Blood Test
Monitoring made simple.View Blood Test
Partner link: PDP may earn a commission at no cost to you.
Simple timing framework
Baseline
Discuss baseline labs before starting, especially with diabetes risk, sleep apnea, edema, thyroid disease, pituitary history, or cancer history.
Follow-up
Re-check IGF-1 and metabolic markers after 6-8 weeks or after meaningful dose changes.
Longer term
For longer protocols, review GH-axis and metabolic trends every 3-6 months with a clinician.
How to interpret the labs
IGF-1 should be interpreted with age, symptoms, and baseline values. Fluid retention, joint pain, numbness, sleep apnea symptoms, and glucose changes matter during GH-axis protocols. Cancer history or active malignancy concerns require clinician-guided review before GH-axis stimulation is considered.
Do not wait for routine labs
Rapid swelling, severe headaches, vision changes, chest pain, or shortness of breath needs medical review. New numbness, wrist pain, or worsening sleep apnea symptoms should be discussed with a clinician.
FAQ
Q1: What is the starting dose of sermorelin?
Common adult research-context starting guidance is 100-200 mcg subQ at bedtime for the first 1-2 weeks, then titrating to 200-300 mcg nightly. The historical FDA-era pediatric label used 0.2-0.3 mg/day. Adult protocols are typically adjusted based on response, sleep changes, and IGF-1 lab trends. This is not a dosing recommendation - work with a licensed clinician.
Q2: How much BAC water do you use to reconstitute a 10 mg sermorelin vial?
A common research-context setup is 3 mL of bacteriostatic water in a 10 mg vial, which gives a 3,333 mcg/mL concentration. On a U-100 insulin syringe, that produces clean whole-unit doses: 100 mcg = 3 units, 200 mcg = 6 units, 300 mcg = 9 units. For other vial sizes or water volumes, recheck with the PepPal calculator.
Q3: How many units of sermorelin should I inject?
It depends on your vial size and how much BAC water you used. With the common 10 mg vial plus 3 mL BAC water setup, 200 mcg equals 6 units on a U-100 syringe and 300 mcg equals 9 units. For any other setup, use the calculator linked in this protocol to get the exact unit count.
Q4: What is sermorelin's half-life?
Sermorelin's plasma half-life is approximately 11-12 minutes after either IV or subQ injection, per Ishida et al. (2020) and the FDA-era prescribing data. Plasma clearance is in the 2.4-2.8 L/min range. The growth hormone pulse triggered by sermorelin lasts longer than the parent peptide stays in circulation.
Q5: Is sermorelin FDA-approved in 2026?
Sermorelin was FDA-approved in 1990 (diagnostic use) and 1997 (pediatric GH deficiency, brand name Geref). Serono Laboratories voluntarily discontinued Geref in 2008 due to manufacturing difficulties, not safety concerns. As of June 2026, there is no currently marketed FDA-approved sermorelin product. However, sermorelin still sits in FDA 503A Category 1, which means licensed compounding pharmacies can legally prepare it with a prescription.
Q6: Is sermorelin legal to compound in 2026?
Yes. Sermorelin remains in FDA 503A Category 1, which means licensed 503A and 503B compounding pharmacies can legally prepare it for patients with a valid prescription. This is different from most other research peptides (BPC-157, CJC-1295, ipamorelin, TB-500, and others), which sit in Category 2 and cannot be legally compounded.
Q7: What are the most common side effects of sermorelin?
Across 350 FDA-era trial patients, the most common side effect was a mild injection-site reaction - pain, swelling, or redness - in about 1 in 6 participants. Only 3 of 350 patients discontinued because of it. Less common effects (each under 1%) included headache, flushing, dizziness, difficulty swallowing, drowsiness, and hives. About 6.5% developed hypothyroidism during trials, which is why thyroid labs are standard monitoring.
Q8: What results can be expected from sermorelin?
Practitioner timelines and FDA-era data line up on a similar pattern: sleep and recovery changes often appear in 2-4 weeks. Body-composition shifts and IGF-1 increases usually need 3-6 months of consistent nightly dosing. Adult-population endpoint data outside practitioner literature is limited, so individual response varies.
Q9: How does sermorelin compare to tesamorelin and CJC-1295?
All three target the GHRH receptor, but they differ in half-life, dosing, and regulatory status. Sermorelin: ~12 minute half-life, nightly, 503A Category 1. Tesamorelin: ~26-38 minute half-life, daily, FDA-approved for HIV-associated lipodystrophy. CJC-1295 (DAC): ~6-8 day half-life, weekly, 503A Category 2 (cannot be legally compounded). See the Tesamorelin protocol and CJC-1295 (DAC) protocol for full details.
Q10: Should sermorelin be taken at night?
Most research-context protocols use sermorelin 30-60 minutes before bed on an empty stomach. The body's biggest natural growth hormone pulse happens during early sleep, and bedtime dosing rides along with that pulse. Eating raises insulin, which blunts the GH response, so most protocols wait 60-90 minutes after the last meal before injecting.
Q11: What vial sizes does sermorelin come in?
Common research-channel sermorelin vial sizes include 2 mg, 5 mg, 9 mg, 10 mg, and 15 mg lyophilized formats. The 10 mg vial is widely available from current compounded and research suppliers. Smaller vials (2 mg, 5 mg) give the cleanest whole-unit syringe math. Larger vials last longer once reconstituted - but remember the 28-day reconstituted-solution shelf life.
Q12: How should reconstituted sermorelin be stored?
Store reconstituted sermorelin upright in the refrigerator at 2-8°C (36-46°F), protect from light, and use within 28 days. Do not freeze reconstituted sermorelin. Discard if the solution is cloudy, discolored, or has any visible particles. Brief room-temperature windows (such as travel) are usually fine, but get it back into refrigeration as soon as possible.
Q13: Can sermorelin be stacked with ipamorelin?
Community protocols often discuss pairing sermorelin (a GHRH analogue) with ipamorelin (a GH secretagogue/GHRP) at bedtime to recruit both signaling pathways. Direct stack-specific clinical trial evidence is limited, and adding compounds increases the safety and quality-control surface area. Read the PepPal Peptide Stacking 101 guide before combining compounds.
Q14: Is this page medical advice?
No. This is an educational research reference. It summarizes published FDA-era data, pharmacokinetic literature, and practitioner-derived protocol structures so you have a clear starting point for a conversation with a licensed clinician. It is not a treatment plan and does not replace medical guidance.
Sources & Research
1. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications (2020) 2. Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging (2006) 3. Cunha JP. Sermorelin Acetate prescribing information. RxList (FDA-era label content, rev. 10/2/2001) (2022) 4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (503A Category 1 / Category 2 list). FDA.gov (2026) 5. U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (503A Bulks List review). FDA.gov advisory committee calendar (2026) 6. Mayo Clinic. Sermorelin (injection route) - side effects and dosage. Mayo Clinic Drugs & Supplements (2025) 7. DrugBank. Sermorelin (DB00010) drug profile. DrugBank Online (2026) 8. PubChem. Sermorelin (CID 16132413). PubChem (NCBI) (2026) 9. Merriam GR, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatrica Supplement (1993) 10. Frier Levitt Attorneys at Law. Regulatory Status of Peptide Compounding in 2025 (sermorelin and NAD+ as Category 1 examples). Frier Levitt (2026) 11. ScienceDirect Topics. Sermorelin summary and references. ScienceDirect (Elsevier) (2025)
Related Dosing Protocols
Ipamorelin protocolTesamorelin protocolCJC-1295 (No DAC) protocolCJC-1295 (DAC) protocolCJC-1295 + Ipamorelin GH pulse stack
Educational research reference
This page is an educational research reference, not medical advice or a treatment plan. Sermorelin was previously FDA-approved (Geref, discontinued 2008) and as of June 2026 remains legally compoundable through 503A and 503B pharmacies with a valid prescription. Always work with a licensed clinician for personal protocols.
Calculate vial math
Use the PepPal calculator for exact syringe units across any vial size and BAC water volume.Open Calculator
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: June 2026
Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.
Share this page